On the tumor side, tumor cells make up a microenvironment that inhibits NK cell activity by altering the balance between NK activating and inhibitory receptors such as reducing NK activating receptor NKG2D and CD16, secreting inhibitory factors such as transforming growth factor beta (TGF-β), IL-6 and IL-10, shedding NKG2D ligands such as MHC class I chain-related protein A (MICA) and MHC class I chain-related protein B (MICB), and recruiting suppressive immune cells such as Tregs and myeloid derived suppressor cells (40). The gene discussed is KLRK1; the disease is neoplasm.